Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Montevialeon Jan 26, 2018 12:01pm

219 Views

Post# 27441318

RE:RE:NEWS - Kalytera Issues Shares to Salzman Group for Payment

As per their agreement, I recall reading the Salzman Group has to liquidate their shares within three days of receiving them.

SizzlinSteaks wrote: Love the fact the Salzman Group prefers shares over payment. It makes for a win win situation. Salzman Group gets cheap paper and Kalytera keeps cash in the till.

SizzlinSteaks wrote:
Kalytera Announces Issuance of Shares under Services Agreement with The Salzman Group of Israel

26 Jan 2018 08:02 ET

GlobeNewswire
Kalytera Therapeutics, Inc. (TSX-V:KALY) (OTCQB:KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 396,015 common shares of the Company ("Common Shares") to The Salzman Group in payment of an invoice issued under the services agreement with The Salzman Group previously announced on December 7, 2017 (the "Agreement"). Under the Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease.

The invoice owing to The Salzman Group is in the amount of US$112,798 (or C$139,000.98 based on the daily average exchange rate for January 25, 2018 published by the Bank of Canada). The number of Common Shares to be issued is based on a deemed issue price of C$0.351 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on January 25, 2018, the trading day prior to the Company's election to pay the debt in Common Shares. The Common Shares are expected to be issued to The Salzman Group on or about January 31, 2018.